P084 Willingness of people treated with elexacaftor/tezacaftor/ivacaftor (ETI) to participate in randomized clinical trials of new modulators and inhaled antibiotics

Donald R. VanDevanter,Katherine Odem‐Davis, I. Emerman,J. Young,Michael W. Konstan,Edith T. Zemanick, N. Mayer-Hamblett

Journal of Cystic Fibrosis（2023）

引用 0|浏览1

暂无评分

摘要

Objectives: Future CF drug development will require clinical trial participation by people with CF (pwCF) benefitting from the CFTR modulator elexacaftor/tezacaftor/ivacaftor (ETI).

查看译文

关键词

inhaled antibiotics,clinical trials,p084 willingness,elexacaftor/tezacaftor/ivacaftor

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要